1. Home
  2. IIF vs SGMT Comparison

IIF vs SGMT Comparison

Compare IIF & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley India Investment Fund Inc.

IIF

Morgan Stanley India Investment Fund Inc.

HOLD

Current Price

$26.88

Market Cap

252.4M

Sector

Finance

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.33

Market Cap

238.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
IIF
SGMT
Founded
1993
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
252.4M
238.7M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
IIF
SGMT
Price
$26.88
$6.33
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$29.75
AVG Volume (30 Days)
45.4K
541.5K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
13.94%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.95
$1.73
52 Week High
$24.41
$11.41

Technical Indicators

Market Signals
Indicator
IIF
SGMT
Relative Strength Index (RSI) 52.19 40.01
Support Level $26.39 $5.95
Resistance Level $26.82 $6.58
Average True Range (ATR) 0.27 0.39
MACD 0.02 -0.05
Stochastic Oscillator 43.75 28.46

Price Performance

Historical Comparison
IIF
SGMT

About IIF Morgan Stanley India Investment Fund Inc.

Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: